Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy.

ABSTRACT:

Background and purpose

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that enhance the immune response against cancer cells. ICIs are generally well tolerated, although endocrine immune-related adverse events (irAEs) are common. We investigated the risk factors for thyroid irAEs in patients treated with ICIs. Moreover, we evaluated the clinical outcome of subjects who became hypothyroid compared to euthyroid patients.

Patients and methods

We retrospectively analyzed a series of 195 consecutively subjects treated with ICIs for metastatic tumors at the University of Naples "Federico II" between January 2014 and March 2020. Only subjects tested for thyroid function before and during the treatment with ICIs were included.

Results

In the 96 patients treated

SUBMITTER: Luongo C 

PROVIDER: S-EPMC8357750 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature